Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Morrow

Showing results (651-660 of 942) with videos related to

Pageof 95
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Journal of the American College of Cardiology|October 18, 2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 18, 2026
Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and painNour Farah, Simon Charbonneau, Sarah A Morrow, et al.
Circulation|March 17, 2005
Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatmentMarc S Sabatine, Gavin J Blake, Mark H Drazner, et al.
Diabetes Care|October 14, 2011
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsAmparo de la Peña, Matthew Riddle, Linda A Morrow, et al.
Diabetes Care|June 6, 2013
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesRalph A DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2020
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapsesSarah A Morrow, Devon Conway, Tom Fuchs, et al.
Journal of the American College of Cardiology|August 24, 2019
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT TrialArman Qamar, Robert P Giugliano, Erin A Bohula, et al.
The American Journal of Cardiology|December 18, 2007
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromesRobert W Yeh, Stephen D Wiviott, Robert P Giugliano, et al.
Journal of Diabetes Science and Technology|November 27, 2020
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin RequirementsXiaosu Ma, Charles T Benson, Randy Prescilla, et al.
Pageof 95

Showing results (651-660 of 942) with videos related to

Sort By:
Pageof 95
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 27, 2010
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeksS A Morrow, P W O'Connor, C H Polman, et al.
Journal of the American College of Cardiology|October 18, 2005
Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trialKausik K Ray, Christopher P Cannon, Richard Cairns, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|May 18, 2026
Discrepancy between subjective and objective cognitive function in multiple sclerosis and association with mood, fatigue, and painNour Farah, Simon Charbonneau, Sarah A Morrow, et al.
Circulation|March 17, 2005
Influence of race on death and ischemic complications in patients with non-ST-elevation acute coronary syndromes despite modern, protocol-guided treatmentMarc S Sabatine, Gavin J Blake, Mark H Drazner, et al.
Diabetes Care|October 14, 2011
Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjectsAmparo de la Peña, Matthew Riddle, Linda A Morrow, et al.
Diabetes Care|June 6, 2013
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetesRalph A DeFronzo, Marcus Hompesch, Sreeneeranj Kasichayanula, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 1, 2020
Quantifying cognition and fatigue to enhance the sensitivity of the EDSS during relapsesSarah A Morrow, Devon Conway, Tom Fuchs, et al.
Journal of the American College of Cardiology|August 24, 2019
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT TrialArman Qamar, Robert P Giugliano, Erin A Bohula, et al.
The American Journal of Cardiology|December 18, 2007
Effect of thrombocytopenia on outcomes following treatment with either enoxaparin or unfractionated heparin in patients presenting with acute coronary syndromesRobert W Yeh, Stephen D Wiviott, Robert P Giugliano, et al.
Journal of Diabetes Science and Technology|November 27, 2020
Pharmacokinetics and Pharmacodynamics of Human Regular U-500 Insulin Administered via Continuous Subcutaneous Insulin Infusion Versus Subcutaneous Injection in Adults With Type 2 Diabetes and High-Dose Insulin RequirementsXiaosu Ma, Charles T Benson, Randy Prescilla, et al.
Pageof 95